Search

Your search keyword '"Sharma, RA"' showing total 782 results
Start Over Author "Sharma, RA"
782 results on '"Sharma, RA"'

24. Quality of life in the FOXFIRE, SIRFLOX and FOXFIRE-global randomised trials of selective internal radiotherapy for metastatic colorectal cancer

Author

Wolstenholme, J, Fusco, F, Gray, AM, Moschandreas, J, Virdee, PS, Love, S, Van Hazel, G, Gibbs, P, Wasan, HS, Sharma, RA, Wolstenholme, J, Fusco, F, Gray, AM, Moschandreas, J, Virdee, PS, Love, S, Van Hazel, G, Gibbs, P, Wasan, HS, and Sharma, RA

Abstract

Selective internal radiotherapy (SIRT) is a liver-directed treatment involving the injection of yttrium-90 microspheres into the blood supply of liver tumours. There are very few studies assessing health-related quality of life (HRQOL) in patients treated with SIRT. Patients with liver metastases from colorectal cancer (CRC) were randomised in the FOXFIRE (FFr; ISRCTN83867919), SIRFLOX (SF; NCT00724503) and FOXFIRE-Global (FFrG; NCT01721954) trials of first-line oxaliplatin-fluorouracil (FOLFOX) chemotherapy combined with SIRT versus FOLFOX alone. HRQOL was assessed using the three-level EQ-5D, European Organisation for Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) and EORTC Colorectal Liver Metastases cancer module (EORTC QLQ-LMC21) at baseline, ≤3 months, 6 months, 12 months and annually thereafter from randomisation, and at disease progression. Analyses were conducted on an intention-to-treat basis. In total, 554 patients were randomised to SIRT + FOLFOX and 549 patients to FOLFOX alone. HRQOL was statistically significant lower in SIRT + FOLFOX patients ≤3 months after SIRT administration in all three instruments, particularly global health, physical and role functioning and symptoms of fatigue, nausea/vomiting and appetite loss. By accepted thresholds, these differences were deemed not clinically important. Differences between SIRT + FOLFOX and FOLFOX alone over the 2-year follow up and at disease progression were also not clinically important. Although there is some decrease in HRQOL for up to 3 months following SIRT, the addition of SIRT to FOLFOX chemotherapy does not change HRQOL to a clinically important degree in metastatic CRC patients.

Published
2020

40. Hepatic resection following selective internal radiotherapy in the FOXFIRE clinical trial: survival, safety, and histopathology

Author

Virdee, PS, Winter, H, Rassam, J, Goldin, R, Wasan, HS, and Sharma, RA

Abstract

Colorectal cancer (CRC) commonly metastasises to the liver and is a leading cause of cancer-related death. The FOXFIRE trial compared the safety and efficacy of radiosensitising chemotherapy (OxMdG: oxaliplatin, 5-fluorouracil and folic acid) with selective internal radiotherapy (SIRT) using yttrium-90 resin microspheres (SIR-Spheres®; Sirtex Medical Limited) to OxMdG alone as first-line management for liver-dominant metastatic CRC. In patients downsized to potentially-curative hepatic resection, we explored survival, safety, and histopathological findings.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results